Condition: Autosomal Dominant Polycystic Kidney · Obesity · Sponsor: University of Colorado, Denver
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.
This description comes directly from the study's public registry record.
Kristen Nowak, PhD, MPH · 3037244842 · Kristen.Nowak@cuanschutz.edu
Diana George · 303-724-1684 · Diana.George@cuanschutz.edu
Always discuss trial participation with your own doctor first.
| University of Colorado - Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06582875